针对慢性髓性白血病肿瘤干细胞的新型治疗药物。
Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia.
机构信息
Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA.
出版信息
Anticancer Agents Med Chem. 2010 Feb;10(2):111-5. doi: 10.2174/187152010790909326.
Abstract
Chronic myeloid leukemia (CML) is induced by the BCR-ABL oncogene, a product of Philadelphia (Ph) chromosome. The BCR-ABL kinase inhibitor imatinib is a standard treatment for Ph+ leukemia, and has been shown to induce a complete hematologic and cytogenetic response in most chronic phrase CML patients. However, imatinib does not cure CML, and one of the reasons is that imatinib does not kill leukemia stem cells (LSCs) in CML both in vitro and in vivo. Recently, several new targets or drugs have been reported to inhibit LSCs in cultured human CD34+ CML cells or in mouse model of BCR-ABL induced CML, including an Alox5 pathway inhibitor, Hsp90 inhibitors, omacetaxine, hedgehog inhibitor and BMS-214662. Specific targeting of LSCs but not normal stem cell is a correct strategy for developing new anti-cancer therapies in the future.
摘要
慢性髓性白血病（CML）是由 BCR-ABL 癌基因引起的，该基因是费城（Ph）染色体的产物。BCR-ABL 激酶抑制剂伊马替尼是 Ph+白血病的标准治疗方法，已证明它可诱导大多数慢性期 CML 患者的完全血液学和细胞遗传学反应。然而，伊马替尼并不能治愈 CML，其中一个原因是伊马替尼在体外和体内均不能杀死 CML 中的白血病干细胞（LSCs）。最近，据报道，几种新的靶点或药物可抑制培养的人 CD34+CML 细胞或 BCR-ABL 诱导的 CML 小鼠模型中的 LSCs，包括 Alox5 途径抑制剂、Hsp90 抑制剂、奥马曲星、 hedgehog 抑制剂和 BMS-214662。特异性靶向 LSCs 而不是正常干细胞是未来开发新抗癌疗法的正确策略。
相似文献
1
Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia.
Anticancer Agents Med Chem. 2010 Feb;10(2):111-5. doi: 10.2174/187152010790909326.
2
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
Leukemia. 2009 Aug;23(8):1446-54. doi: 10.1038/leu.2009.52. Epub 2009 Mar 26.
3
Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Clin Cancer Res. 2015 Feb 15;21(4):833-43. doi: 10.1158/1078-0432.CCR-13-3317. Epub 2014 Dec 11.
4
Characterization of cancer stem cells in chronic myeloid leukaemia.
Biochem Soc Trans. 2007 Nov;35(Pt 5):1347-51. doi: 10.1042/BST0351347.
5
The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia.
Cell Cycle. 2009 Nov 1;8(21):3488-92. doi: 10.4161/cc.8.21.9852. Epub 2009 Nov 19.
6
Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Clin Epigenetics. 2020 May 19;12(1):69. doi: 10.1186/s13148-020-00839-z.
7
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865.
8
Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells.
Blood. 2013 Oct 24;122(17):3086-8. doi: 10.1182/blood-2013-04-494773.
9
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Blood. 2008 Mar 1;111(5):2843-53. doi: 10.1182/blood-2007-09-112573. Epub 2007 Dec 21.
10
Omacetaxine mepesuccinate in chronic myeloid leukemia.
Expert Opin Pharmacother. 2014 Nov;15(16):2397-405. doi: 10.1517/14656566.2014.964642.
引用本文的文献
1
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.
Blood. 2023 Jul 6;142(1):73-89. doi: 10.1182/blood.2022016896.
2
Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway.
Oncotarget. 2017 Dec 14;9(3):3267-3277. doi: 10.18632/oncotarget.23231. eCollection 2018 Jan 9.
3
Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells.
Oncotarget. 2017 Feb 7;8(6):10025-10036. doi: 10.18632/oncotarget.14324.
4
Omacetaxine mepesuccinate: a new treatment option for patients with chronic myelogenous leukemia.
J Adv Pract Oncol. 2013 Jul;4(4):257-62.
5
Effects of quercetin on hedgehog signaling in chronic myeloid leukemia KBM7 cells.
Chin J Integr Med. 2014 Oct;20(10):776-81. doi: 10.1007/s11655-014-1817-3. Epub 2014 Jun 13.
6
Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
Mol Pharm. 2013 Jan 7;10(1):270-7. doi: 10.1021/mp300405n. Epub 2012 Dec 18.
7
Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.
Oncotarget. 2011 Sep;2(9):713-27. doi: 10.18632/oncotarget.333.
8
Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses.
Expert Opin Investig Drugs. 2011 Feb;20(2):239-54. doi: 10.1517/13543784.2011.547852.
9
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
J Hematol Oncol. 2010 Nov 26;3:47. doi: 10.1186/1756-8722-3-47.
10
The tissue-specific stem cell as a target for chemoprevention.
Stem Cell Rev Rep. 2011 Jun;7(2):307-14. doi: 10.1007/s12015-010-9205-7.
本文引用的文献
1
BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.
Blood. 2009 Nov 5;114(19):4186-96. doi: 10.1182/blood-2009-05-219550. Epub 2009 Sep 8.
2
Following the hedgehog to new cancer therapies.
N Engl J Med. 2009 Sep 17;361(12):1202-5. doi: 10.1056/NEJMe0906092. Epub 2009 Sep 2.
3
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia.
Nat Genet. 2009 Jul;41(7):783-92. doi: 10.1038/ng.389. Epub 2009 Jun 7.
4
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
Leukemia. 2009 Aug;23(8):1446-54. doi: 10.1038/leu.2009.52. Epub 2009 Mar 26.
5
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia.
Nature. 2009 Apr 9;458(7239):776-9. doi: 10.1038/nature07737.
6
beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Leukemia. 2009 Jan;23(1):109-16. doi: 10.1038/leu.2008.262. Epub 2008 Sep 25.
7
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.
Cancer Cell. 2008 Sep 9;14(3):238-49. doi: 10.1016/j.ccr.2008.08.003.
8
Stems cells and the pathways to aging and cancer.
Cell. 2008 Feb 22;132(4):681-96. doi: 10.1016/j.cell.2008.01.036.
9
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Blood. 2008 Mar 1;111(5):2843-53. doi: 10.1182/blood-2007-09-112573. Epub 2007 Dec 21.
10
Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo.
Cancer Cell. 2007 Dec;12(6):528-41. doi: 10.1016/j.ccr.2007.11.003.
Zotero 插件